Abstract
Objective: We report the results of pharmacogenomics-based antidepressant treatment (PGXt) results in treating treatment- resistant major depressive disorder (TRD) patients in real practice. Methods: Nine patients were prescribed Neuropharmagen? for selection of antidepressants for individual patient and their clinical outcomes were followed. Results: After treatment by PGXt results from current antidepressants, substantial reduction of depressive symptoms was observed at some point and maintained during observation period in six patients. Conclusion: Our case series potentially shows the clinical utility and benefit of PGXt for treatment of TRD patients.
| Original language | English |
|---|---|
| Pages (from-to) | 160-165 |
| Number of pages | 6 |
| Journal | Clinical Psychopharmacology and Neuroscience |
| Volume | 19 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 2021 |
Bibliographical note
Publisher Copyright:© 2021 Korean College of Neuropsychopharmacology. All rights reserved.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Antidepressive agent
- Clinical outcome
- Depressive disorder
- Treatment
- Treatment-resistance
Fingerprint
Dive into the research topics of 'A practical utility and benefit of pharmacogenetic-based antidepressant treatment strategy for major depressive disorder patients with difficult-to-treat'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver